Dong-A ST Applies for Phase 3 Clinical Trial of Chronic Plaque Psoriasis Treatment

[Asia Economy Reporter Gong Byung-sun] Dong-A ST announced on the 23rd that it has applied for approval of the Phase 3 clinical trial plan for the chronic plaque psoriasis treatment DMB-3115 from the clinical approval institution Georgia BIOMAPAS.

Dong-A ST explained that the statistical probability of the clinical trial drug receiving final approval is about 10%, and therefore investment should be made cautiously.